Medtronic (NYSE:MDT) Upgraded to Hold at Barclays

Barclays upgraded shares of Medtronic (NYSE:MDT) to a hold rating in a report issued on Wednesday,Zacks reports.

MDT has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 4th. Wells Fargo & Company raised their price objective on Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 2nd. TD Cowen restated a “buy” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, September 30th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $92.00 price target on shares of Medtronic in a research report on Thursday, September 3rd. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.92.

Medtronic Price Performance

MDT opened at $85.51 on Wednesday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $109.38 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.98 and a beta of 0.55. The company has a 50 day moving average of $90.18 and a two-hundred day moving average of $84.75. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the prior year, the firm earned $1.26 EPS. The firm’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts expect that Medtronic will post 5.98 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.4%. Medtronic’s payout ratio is 70.94%.

Insider Activity

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Hedge funds have recently modified their holdings of the stock. Gradient Investments LLC boosted its holdings in Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock valued at $38,842,000 after purchasing an additional 18,509 shares in the last quarter. Czech National Bank grew its stake in Medtronic by 4.7% during the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after buying an additional 16,292 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Medtronic by 14.8% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 149,708 shares of the medical technology company’s stock worth $12,918,000 after buying an additional 19,315 shares in the last quarter. Verity & Verity LLC increased its holdings in shares of Medtronic by 5.1% during the second quarter. Verity & Verity LLC now owns 229,707 shares of the medical technology company’s stock worth $17,970,000 after buying an additional 11,197 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its stake in shares of Medtronic by 5.3% in the fourth quarter. Panagora Asset Management Inc. now owns 749,064 shares of the medical technology company’s stock valued at $71,955,000 after acquiring an additional 37,518 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic finalized an exchange ratio of 4.5939 MiniMed shares for each Medtronic ordinary share accepted in the split-off. The company will offer up to 225.4 million MiniMed shares and may exchange an additional 27.45 million shares if the offer is oversubscribed. The transaction could sharpen Medtronic’s focus on medical devices while giving shareholders direct exposure to MiniMed. Medtronic Announces Final Exchange Ratio
• Positive Sentiment: Medtronic appointed Felicia Kurz as vice president and general manager of its cardiac ablation business. The move comes as demand for its pulsed-field ablation products supports strong electrophysiology growth, reinforcing investor confidence in one of the company’s faster-growing businesses. Medtronic Names Felicia Kurz
• Positive Sentiment: The American Medical Association granted permanent Category I CPT codes for Medtronic’s Altaviva tibial neuromodulation implant and Symplicity Spyral renal denervation system. More established reimbursement may improve physician adoption and support future revenue growth. Medtronic CPT Code Win
• Neutral Sentiment: Medtronic’s FY2026 impact report said the company’s technologies served more than 82 million patients worldwide. The report highlights the company’s scale and social impact but offers limited immediate financial guidance. Medtronic FY2026 Impact Report
• Negative Sentiment: The MiniMed split-off creates near-term uncertainty over Medtronic’s share count, ownership structure and valuation. Investors may also be repositioning around the exchange ratio, contributing to elevated trading activity and pressure on MDT while the transaction is completed. Medtronic MiniMed Exchange Offer

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.